lamivudine has been researched along with epoxyfarnesyl diazoacetate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexandre, FR; Convard, T; Dousson, CB; Fillgrove, K; Guillon, S; Lai, MT; Meillon, JC; Rahali, H; Rahali, R; Raheem, IT; Small, J; Xu, M | 1 |
| Aoki, M; Desai, DV; Kodama, EN; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Brenner, BG; Ibanescu, RI; Mesplède, T; Oliveira, M; Wainberg, MA; Xu, H | 1 |
| Grobler, JA; Markowitz, M | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; DeJesus, E; Eves, K; Grandhi, A; Hanna, GJ; Hwang, C; Molina, JM; Olsen Klopfer, S; Robertson, MN; Sklar, P; Yazdanpanah, Y | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y | 1 |
1 review(s) available for lamivudine and epoxyfarnesyl diazoacetate
| Article | Year |
|---|---|
Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
Topics: Animals; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; Lamivudine; Macaca mulatta; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Triazoles; Viral Load | 2020 |
2 trial(s) available for lamivudine and epoxyfarnesyl diazoacetate
| Article | Year |
|---|---|
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Dosage Calculations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Triazoles; Young Adult | 2021 |
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles | 2022 |
3 other study(ies) available for lamivudine and epoxyfarnesyl diazoacetate
| Article | Year |
|---|---|
Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine).
Topics: Animals; Antiviral Agents; Cell Line; Chemistry Techniques, Synthetic; Deoxyadenosines; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Conformation; Rats; Reverse Transcriptase Inhibitors; Tissue Distribution | 2018 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Lamivudine; Molecular Sequence Data; Molecular Structure; Organophosphonates; Tenofovir; Thymidine | 2014 |
M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
Topics: Amino Acid Substitution; Anti-HIV Agents; Clinical Trials as Topic; Deoxyadenosines; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2017 |